Michael Yurkowsky
Chief Executive Officer bei INNOVEREN SCIENTIFIC INC.
Vermögen: 306 $ am 31.03.2024
Profil
Michael W.
Yurkowsky is the founder of Deverra Therapeutics, Inc. He currently holds multiple positions.
He is the Chief Executive Officer & Independent Director at Innoveren Scientific, Inc. since 2021.
He is also the Chief Executive Officer at Immuni-T, Inc., the Owner of YP Holdings LLC (Florida), and the President of Jantibody LLC.
In the past, he served as the Director at Vicapsys Life Sciences, Inc. from 2019 to 2022.
He was also a Vice President-Investments at Wachovia Securities LLC from 1997 to 2003.
Additionally, he was the Owner of Trenchant Asset Management Ltd.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
INNOVEREN SCIENTIFIC INC
1,30% | 10.05.2023 | 9 261 ( 1,30% ) | 306 $ | 31.03.2024 |
Aktive Positionen von Michael Yurkowsky
| Unternehmen | Position | Beginn |
|---|---|---|
| INNOVEREN SCIENTIFIC INC. | Chief Executive Officer | 06.12.2021 |
| YP Holdings LLC (Florida) | Corporate Officer/Principal | - |
Deverra Therapeutics, Inc.
 Deverra Therapeutics, Inc. BiotechnologyHealth Technology Deverra Therapeutics, Inc. engages in the development of platform technology for the generation of off-the-shelf allogeneic cellular immunotherapies. It offers a notch-mediated cell expansion platform for the production of progenitor blood and immune cells for clinical application. The company is headquartered in Seattle, WA. | Chief Executive Officer | - |
| Immuni-T, Inc. | Chief Executive Officer | - |
Jantibody LLC
 Jantibody LLC Pharmaceuticals: MajorHealth Technology Part of Innoveren Scientific, Inc., Jantibody LLC is a private company that provides cancer treatment drugs. The company is based in St. Augustine, FL. Jantibody was acquired by Innoveren Scientific, Inc. on September 08, 2022 for $0.23 million. | President | - |
Ehemalige bekannte Positionen von Michael Yurkowsky
| Unternehmen | Position | Ende |
|---|---|---|
| VICAPSYS LIFE SCIENCES, INC. | Director/Board Member | 22.09.2022 |
Wachovia Securities LLC
 Wachovia Securities LLC Investment Banks/BrokersFinance Wachovia Securities LLC offered equity, fixed income, and structured products. It was founded in 2001 and was headquartered in St. Louis, MO. | Corporate Officer/Principal | 01.08.2003 |
| Trenchant Asset Management Ltd. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VICAPSYS LIFE SCIENCES, INC. | Health Technology |
| INNOVEREN SCIENTIFIC INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Wachovia Securities LLC
Wachovia Securities LLC Investment Banks/BrokersFinance Wachovia Securities LLC offered equity, fixed income, and structured products. It was founded in 2001 and was headquartered in St. Louis, MO. | Finance |
| Trenchant Asset Management Ltd. | |
| YP Holdings LLC (Florida) | |
Deverra Therapeutics, Inc.
Deverra Therapeutics, Inc. BiotechnologyHealth Technology Deverra Therapeutics, Inc. engages in the development of platform technology for the generation of off-the-shelf allogeneic cellular immunotherapies. It offers a notch-mediated cell expansion platform for the production of progenitor blood and immune cells for clinical application. The company is headquartered in Seattle, WA. | Health Technology |
| Immuni-T, Inc. | |
Jantibody LLC
Jantibody LLC Pharmaceuticals: MajorHealth Technology Part of Innoveren Scientific, Inc., Jantibody LLC is a private company that provides cancer treatment drugs. The company is based in St. Augustine, FL. Jantibody was acquired by Innoveren Scientific, Inc. on September 08, 2022 for $0.23 million. | Health Technology |
